



For Immediate Release
APRIL 18th, 2020

MEDI-PURE FILES INTERNATIONAL APPLICATION UNDER WIPO'S PATENT COOPERATION TREATY (PCT) FOR ANXIOLYTIC FORMULATIONS

Vancouver, BC – April 18 2019 – Medipure Holdings Inc. (“Medipure” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Medipure Pharmaceuticals Inc., has filed patent applications and confirmed receipts with International Applications Under WIPO’s Patent Cooperation Treaty (PCT), an important step in providing intellectual and commercial protection for MP-20X as a endocannabinoid system-based prescription Anxiolytic medications.

Filing these applications is essential to protect the invention in 153 countries that include most jurisdictions in North America, Europe, South America and Asia Pacific and the major industrialized countries (with a few exceptions of Argentina, and Taiwan). Medipure has separately filled patent applications and confirmed receipts in Argentina and Taiwan.

“Medipure has many lines of drug formulations in development for the treatment of a number of diseases,” said CEO, Boris Weiss. “We are moving closer to our goal of leadership in endocannabinoid system-based prescription medications and advancing our drug pipeline to offer patients safe and effective therapeutics.”

Dr. Nihar Pandey, Medipure's Chief Scientific Officer commented, "The global rise in benzodiazepine and SSRI class of prescription drugs has raised the concerns as these are highly addictive medications with severe side effects. Medipure is developing an endocannabinoid-targeting novel anxiolytic formulation MP-20X with no addictive and psychoactive effects for the treatment of many psychotic conditions”

Confirmation of the filed patent application was received February 7, 2020. Additionally, Taiwanese patent application (109103948), and Argentinean patent application (P200100344) were filed on February 7, 2020 as they are recognized by the Company as pharmaceutical targets but are outside of the WIPO PCT treaty. Exemplary claims from the allowed patent applications are as follows:

CANNABINOID RECEPTOR AGONISTS AND SERINE HYDROLASE ENZYME INHIBITOR BASED ANXIOLYTIC THERAPEUTIC PRODUCT.

FIELD OF INVENTION

This disclosure relates to formulations for treating mood disorders. Specifically, the present disclosure is related to formulations that combine one or more than one cannabinoid receptor agonist and one or more than one serine hydrolase enzyme inhibitor to treat mood disorders.

Information about Medipure Holdings Inc. is available at: <http://medipurepharmaceuticals.com>

About Medipure:

Medipure Pharmaceuticals Inc., a wholly owned subsidiary under Medipure Holdings Inc., is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid



system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH).

Medipure's research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.

Disclaimer:

The material contained herein is provided solely for your general knowledge and is not intended to be a comprehensive review of all matters and developments concerning Medipure Holdings Inc. and Medipure Pharmaceuticals Inc. (collectively, "Medipure"). Medipure makes no representation or warranty regarding, and assumes no responsibility for, the use, validity, accuracy, completeness, reliability, or currency of any claims, statements, or information in this summary. This information does not constitute and should not be interpreted as an offer or the solicitation of an offer for the purchase of any securities of Medipure and is not intended in any way to qualify, modify, or supplement any information disclosed under the corporate and securities laws of any jurisdiction applicable to Medipure. No securities commission or similar authority in Canada or any other country or jurisdiction has in any way passed on any of the information contained in this summary.

Any "forward looking statements" contained herein within the meaning of standard securities legislation. Future events and financial and operating results are subject to risks and uncertainties. Medipure's actual results, performance, or achievements could differ materially from those expressed or implied by such statements. Medipure disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Any disclosure, unauthorized use, or duplication of this document or of any of the information contained herein for other than the specific purpose for which it was disclosed is expressly prohibited, except as Medipure may agree to in writing.

Contact:

info@medipurepharma.com

Medipure Pharmaceuticals Inc.
302-267 West Esplanade
North Vancouver, B.C.